Sreelakshmi24’s Blog

where life is all about learning

Archive for the ‘research’ Category

Cadila Pharmaceuticals commissioned a revolutionary research on Cardiac diseases targeted at Asymptomatic Healthy people

leave a comment »

To launch a product that will considerably reduce the mortality due to sudden cardiac disorder, world wide

 

 

Ahmedabad Based Pharma major Cadila Pharmaceuticals, one of the most reputed, Research based, Tech savvy pharmaceutical company in collaboration with McMaster University of Hamilton, Canada, has done a revolutionary research targeted to Asymptomatic Healthy people.

 

Shri I. A. Modi, Chairman Cadila Pharmaceuticals said, “Cadila Pharmaceuticals has carved a niche for itself by being the front runner in introducing research driven innovative products for the benefit of mankind. Worldwide Cardio Vascular diseases are the leading cause of death and disability. Despite the best of diagnostic and therapeutic approaches, the challenge to decrease mortality and morbidity stands, because cardiac malfunction does not necessarily happen in patients with symptoms. Various therapies are currently available for secondary prophylaxis of cardiovascular diseases but none for primary prophylaxis.
Studies show that Cardio Vascular death burden in developed countries were 5.3 million in the year 1990 whereas in developing countries it was 7-8 million. With the burgeoning epidemic of CVD, especially in low income countries, effective preventive strategies need to be urgently implemented. Cadila Pharma took it as a challenge to develop a therapy to address primary prophylaxis.”

Mr J.P Parswani, President, Cadila Pharmaceuticals Limited commented, “A research team comprising of 57 cardiologists, led by Dr Salim Yusuf, Dean Cardiovascular Services worked for two years at McMaster University, Hamilton to make the hypothesis a success. The Research findings of the same would be revealed by Dr Salim Yusuf on March 30th 2009 at the American College of Cardiology, Orlando, in presence of more than 25,000 cardiologists all over the world. The research team has come up with a new therapy, a new approach, a comprehensive treatment that is going to set a benchmark in the treatment of Cardio Vascular diseases. The launch of this product marks Cadila’s contribution to science, academics and mankind. The Product is not just
a substitute for lifestyle management, but it complements the same.The product would help to bring down the cardiovascular morbidity and mortality.”

Dr Arun Maseeh, Vice President – Medical Services, is of the opinion, “Risk prevention in CVD can be approached from two levels: at the individual level and at population level. And two interventions are available to reduce risk factor levels, namely lifestyle modifications and drugs. Unfortunately lifestyle modifications related interventions have not largely been successful, as individuals were targeted rather that entire population with a few exceptions. It is therefore time to seriously consider drugs to halt the rapid advancement of CVD related mortality, especially in developing countries. The best results are obtained when multiple risk factors a re targeted at the same time. We have tested the hypothesis of Wald and Law, comprehensively in a multicentre, randomized, controlled, double-blind trial – The Indian Polycap Study (TIPS). The trials conducted in 53 hospitals all over India on 2053 healthy people. The Indian Coordinating Center was St. John’s Medical College, Bangalore, and the International Coordinating Center was Population Health Research Institute HHS and McMaster University, Hamilton, Canada.”

For further information please contact:    

medical@cadilapharma.co.in


Advertisements

Piramal Life Sciences initiates Phase II trials of P276 for Mantle Cell Lymphoma

leave a comment »

Piramal Life Sciences Limited (PLSL) announced that it has started phase II trial in USA for its lead cancer compound P 2 76-00 to treat Mantle cell Lymphoma (MCL) and it is the second IND approved by the US FDA for this compound.

MCL is a subtype of non-Hodgkin lymphoma that has 59,000 new cases in the United States each year. Despite the availability of novel agents, MCL remains an incurable disease for most patients, with a median survival of 3 to 5 years. High-dose chemotherapy followed by transplantation has resulted in improvement in response rates and survival compared with conventional therapy, but relapse is nearly universal and not all patients are candidates for this option of aggressive treatment. Therefore, there is still a need for a targeted, safe and effective therapy.

In most of the MCL cases, genetic and epigenetic events result in over expression of cyclin D1 which provide tumour cells a selective growth advantage. Inhibition of cyclins/Cdks, therefore, offers an attractive mechanism for treatment of this cancer. P276 is a new chemical entity that inhibits Cdk4/cyclinD1 and has been found to be well tolerated and safe in two phase I clinical studies carried out in Canada and India. A number of sites in USA will participate in this phase II clinical trial including University of Wisconsin, Madison, where the clinical study will be coordinated by Dr Brad Kahl -a world-renowned authority in Mantle cell Lymphoma.

Dr. (Mrs.) Swati Piramal, Vice Chairperson, PLSL said, ” Piramal Life Sciences aims to reduce the burden of disease by finding new and affordable cures for unmet medical needs. It is a proud moment for Indian research and an important milestone because a drug discovered in India, with global patents is now being tested at world- renowned cancer hospitals in the USA.”

Dr Somesh Sharma, Managing Director, Piramal Life Sciences, stated, ” Piramal Life Sciences is committed to the Group’s values – knowledge, action and care. We nurture breakthrough thinking and follow it up with dynamic, nimble-footed delivery to impact lives of millions of people. The initiation of phase II clinical trials of P276 in mantle cell lymphoma patients in the US further highlights PLSL’s capabilities in developing a compound to address unmet medical needs worldwide.”

For further information, visit http://www.piramallifesciences.com

Written by sreelakshmi

17 January, 2009 at 12:21 pm

Another major source of stem cells – menstrual blood

leave a comment »

Stem cells are one of the most fascinating areas of biology today. But like many growing fields of scientific inquiry, research on stem cells raises scientific questions as quickly as it generates new discoveries.

In India, menstruation blood has been considered as dirty and polluting. There have been a lot of myths, taboos and various practices related to menstruation. In olden times, the lady would be made to sit in some corner, wear only particular clothes, use a separate set of vessels for eating and drinking, and she was not allowed to cook. Other members in the family were not to even go near her, let alone touch her!!! At the end of the period, she would ‘cleanse’ herself by taking a hair bath.

Thankfully, while in some of the homes in rural India these restrictions might still be prevalent; in urban homes these rules seem to have lost effect. However, menstrual blood is still today considered sanitary waste. Yet recent findings have revealed menstrual blood to be a rich and easily accessible source of adult stem cells.

LifeCell is the first and the largest private cord blood stem cell bank and stem cell solutions provider in India which facilitates the cryogenic preservation of umbilical cord blood stem cells at its central facility in Chennai, India. They have been doing research on menstrual blood as a source of stem cells. Here is what Dr. Ajit Kumar, Chief Scientific Officer, LifeCell International has to say:

A woman’s role in society and the family is constantly changing. She dons the role of a daughter, sister, wife, mother, an entrepreneur, a working professional, a friend and much more with élan. The master stem cell or the zygote, wherein human life begins, is created when a woman’s egg is fertilized by her partner’s sperm. Shortly thereafter, this master stem cell begins to multiply into hundreds of millions of cells, including a large number of other stem cells, as the embryo develops during the early stages of pregnancy. The less specialized stem cells give rise to more specialized cell types and the process continues throughout pregnancy leading to the formation of all the cell types within the human body such as skin, muscle, nerve, bone, etc. Following birth and throughout adult life, our bodies continue to produce stem cells that serve as a vital source for regeneration and repair throughout our lifetime.

While the concept of stem cells becomes intuitive if one considers the development of complex organisms such as humans from a single cell such as the zygote and also the constant requirements for repair and replenishment of cells, it is only within the last fifty years that stem cells have been recognized for their therapeutic value. It is these therapeutic applications that have become the primary focus of studies by researchers and scientists from around the world. Since the very first bone marrow transplant in the 1950’s, to the 1980’s and ’90’s, when more than 16,000 stem cell transplants were performed to treat leukemia and immune system diseases, research into regenerative cellular therapies for a wide range of human diseases has rapidly advanced. Most recently, medical researchers have discovered adult stem cells in the endometrial lining of the uterus.

Another path breaking discovery in this area is that menstrual blood itself is a rich source of stem cells and serves as a potential source for promising regenerative therapies to treat heart disease, diabetes, neurological disorders like spinal cord injury, Parkinson’s and Alzheimer’s diseases, in addition to cosmeceutical applications such as anti-aging therapies, to name a few. In simple terms potentially life-saving stem cells are found naturally in menstrual blood.

The Menstrual stem cell comes from the uterine lining (endometrium), which is shed as part of a woman’s menstrual period. These menstrual stem cells are unique because they have many properties and characteristics similar to both bone marrow and embryonic stem cells.

Until now, menstrual blood has been discarded as unsanitary waste. However, as recent research has shown menstrual fluid contains self-renewing stem cells that can be easily collected, processed and cryo-preserved for potential cellular therapies that may emerge in the future. They multiply rapidly and can differentiate into many other types of cells such as neural, cardiac, bone, fat, cartilage and possibly others; demonstrating great potential for cell therapy. Preliminary research suggests that in addition to possible use by the donor, these stem cells may also be used to benefit other family members who are genetically related to the donor, such as perhaps a parent, sibling or child.

More information on stem cells is available on www.lifecellinternational.com

Written by sreelakshmi

6 January, 2009 at 7:32 am

State-of-the-art, fully automated stem cell banking facility setup at Bangalore

leave a comment »

Cryo-Save Group announced the launch of its Indian operations through its 100 percent subsidiary –Cryo-Save India. Cryo-Save India offers a depth of expertise and experience in stem cell banking.

Stem cells are the natural repair kit of the human body. In the last 18 years more than 10000 patients have been treated with cord blood stem cells transplantations in over 150 countries. Umbilical cord blood stem cells have been used over the years in an increasing number of treatments including leukaemia, myelodysplastic syndrome, lymphomas, red cell disorders and more. Currently stem cell research is being done for more than 85 diseases.

Speaking on the occasion V.R. Chandramouli, Managing Director, Cryo-Save India, said, “We are very happy to launch the Indian subsidiary and offer our expertise in adult stem cell banking services in India. A world class stem cell banking service was the need of the hour for a huge market like India and Cryo-Save India will be offering this. We are very keen to extend our footprint to India and we are very excited about the immense market potential for adult stem cell banking or family banking in India. The launch of the Indian operations will mark a new chapter in the quality of stem cell banking services offered. Cryo-Save India will bring in our global expertise, best practices and our vast experience to the Indian customer.

Cryo-Save India will be the only company in India with its unique offering of dual-storage system. They are also the only company that does automatic processing to avoid manual intervention and contamination. The company will be offering the collection and storage of ADULT stem cells derived from cord blood. The services will be available across all metros and other cities.
Cryo-Save has never been, and does not intend to become, involved in the storage or expansion of embryonic stem cells.

Cryo-Save India is headquartered in Bangalore with a state-of-the art, one-of-its-kind, fully automated adult stem cell storage facility. The facility at Bangalore covers 10,000 sq ft with a storage capacity of 150,000 samples, extendable to 300,000 immediately. Cryo-Save India is a 100 percent subsidiary of Cryo-Save Group, which is Europe’s largest adult stem cell storage bank and has its operations in 37 countries over three continents.

For further details click on the following link:

http://www.cryo-save.com/india/index.html

Written by sreelakshmi

29 December, 2008 at 9:42 pm